Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®
Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for its lead candidate, up to now referred to as Modufolin®. Arfolitixorin was recently accepted by World Health Organization (WHO) as the International Non-proprietary Name (INN) for the active ingredient of Isofol's lead product Modufolin®.“We are delighted that the WHO has recognized the unique nature of our compound by accepting arfolitixorin as an INN. This is an important step towards bringing a new drug to market,” said Anders Rabbe, Chief Executive Officer at